A Phase II, Double-Blind, Randomized, Multicenter Trial to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Infants
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 30 Sep 2017
At a glance
- Drugs Pneumococcal-15-valent-vaccine-conjugate (Primary) ; Pneumococcal 7-valent CRM197 vaccine conjugate
- Indications Pneumococcal infections
- Focus Adverse reactions; Pharmacodynamics
- Acronyms V114-008
- Sponsors Merck Sharp & Dohme
- 15 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 11 Apr 2017 Status changed from not yet recruiting to recruiting.
- 12 Dec 2016 New trial record